GFS Advisors LLC Acquires 11,655 Shares of Sanofi (NASDAQ:SNY)

GFS Advisors LLC grew its stake in Sanofi (NASDAQ:SNY) by 1,017.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,800 shares of the company’s stock after acquiring an additional 11,655 shares during the period. GFS Advisors LLC’s holdings in Sanofi were worth $738,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Manning & Napier Advisors LLC acquired a new stake in Sanofi in the 2nd quarter valued at about $13,725,000. Mount Yale Investment Advisors LLC boosted its stake in shares of Sanofi by 44.3% during the 1st quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock worth $2,027,000 after acquiring an additional 12,806 shares during the period. Jennison Associates LLC increased its holdings in shares of Sanofi by 18.9% during the 1st quarter. Jennison Associates LLC now owns 189,622 shares of the company’s stock worth $9,216,000 after acquiring an additional 30,115 shares during the last quarter. Sei Investments Co. raised its stake in Sanofi by 9.3% in the 1st quarter. Sei Investments Co. now owns 554,028 shares of the company’s stock valued at $26,926,000 after acquiring an additional 47,297 shares during the period. Finally, Janney Montgomery Scott LLC lifted its holdings in Sanofi by 10.4% during the 1st quarter. Janney Montgomery Scott LLC now owns 307,627 shares of the company’s stock valued at $14,951,000 after purchasing an additional 29,082 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analyst Upgrades and Downgrades

SNY has been the topic of several research analyst reports. Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com raised Sanofi from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Finally, Argus upped their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi has a consensus rating of “Buy” and a consensus target price of $57.50.

Sanofi Stock Up 0.7 %

SNY stock opened at $53.27 on Friday. The stock has a market capitalization of $135.19 billion, a P/E ratio of 27.18, a price-to-earnings-growth ratio of 1.35 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm has a 50-day moving average price of $55.92 and a 200-day moving average price of $52.00. Sanofi has a 12 month low of $45.00 and a 12 month high of $58.97.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same period in the prior year, the business earned $2.55 earnings per share. As a group, equities research analysts anticipate that Sanofi will post 4.27 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.